Johnson & Johnson (NYSE:BMY) Pharmaceutical Business Review Conference Call September 13, 2018 10:00 AM ET
Executives
Lesley Fishman - Senior Director, IR
Chris DelOrefice - VP, IR
Joaquin Duato - Vice Chairman, Executive Committee
Jennifer Taubert - EVP and Worldwide Chairman, Pharmaceuticals
Mathai Mammen - Global Head, Janssen Research & Development
Analysts
Chris Schott - JP Morgan
Jami Rubin - Goldman Sachs
Larry Biegelsen - Wells Fargo
Olivia Brayer - Barclays
Vamil Divan - Credit Suisse
Josh Jennings - Cowen and Company
Carter Gould - UBS
Travis Steed - Bank of America
Lesley Fishman
Good morning. I’m Lesley Fishman, Senior Director of Investor Relations for Johnson & Johnson. And it is my pleasure to welcome you to today’s review of our Pharmaceutical business.
Joining me today is Chris DelOrefice, our recently appointed Vice President, Investor Relations, and our speakers, Joaquin Duato, Vice Chairman of the Executive Committee of Johnson & Johnson, Jennifer Taubert, Executive Vice President and Worldwide Chairman Pharmaceuticals; and Mathai Mammen, Global Head, Janssen Research & Development.
We are hosting today’s meeting to provide an interim business update since our last biannual review in May 2017, highlighting our strong commercial performance, sharing additional insight into our robust pipeline and offering a focused discussion with our Pharmaceutical management. We solicited input from many of you, and you’ll see that feedback reflected in today’s discussion.
Here is our agenda. You’ll initially hear from Joaquin Duato who’ll share his perspectives on the global Pharmaceutical market and how Johnson & Johnson is positioned to continue to lead the industry.
